featured
Efficacy and Safety of Setmelanotide in Individuals With Severe Obesity Due to LEPR or POMC Deficiency
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Setmelanotide, an MC4R Agonist, in Individuals With Severe Obesity Due to LEPR or POMC Deficiency: Single-Arm, Open-Label, Multicentre, Phase 3 Trials
Lancet Diabetes Endocrinol 2020 Oct 30;[EPub Ahead of Print], K Clément, E van den Akker, J Argente, A Bahm, WK Chung, H Connors, K De Waele, IS Farooqi, J Gonneau-Lejeune, G Gordon, K Kohlsdorf, C Poitou, L Puder, J Swain, M Stewart, G Yuan, M Wabitsch, P KühnenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.